By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Adamas Pharmaceuticals 

1900 Powell Street
Suite 1050
Emeryville  California  94608  U.S.A.
Phone: 510-450-3500 Fax: 510-428-0519


Key Statistics

Ownership: Public

Web Site: Adamas Pharma
Symbol: ADMS



Company News
Should You Buy Adamas Pharma (ADMS) Stock Ahead Of Upcoming PDUFA On August 24? 8/14/2017 6:13:40 AM
Adamas Pharma (ADMS) Reports Recent Achievements And Second Quarter 2017 Financial Results 8/9/2017 1:44:45 PM
Adamas Pharma (ADMS) Reports Inducement Grant To New Chief Financial Officer 7/11/2017 11:19:05 AM
Adamas Pharma (ADMS) Appoints New Chief Financial Officer 6/28/2017 8:32:44 AM
Adamas Pharma (ADMS) Announces Publication Of ADS-5102 Phase III EASE LID Clinical Trial In JAMA Neurology 6/13/2017 10:42:27 AM
Adamas Pharma (ADMS) Presents Expanded Analysis From The ADS-5102 Open-Label Study Showing Tolerability And Durability Out To 88 Weeks 6/9/2017 9:32:27 AM
Adamas Pharma (ADMS) Presents Positive Phase Ia Data Of ADS-4101 (Lacosamide) For The Treatment Of Partial Onset Seizures In Epilepsy 5/22/2017 8:22:21 AM
Adamas Pharma (ADMS) Signs $100 Million Royalty-Backed Note Agreement With Healthcare Royalty Partners 5/11/2017 8:42:48 AM
Adamas Pharma (ADMS) Reports Inducement Grant To New Chief Operating Officer 5/8/2017 10:46:27 AM
Adamas Pharma (ADMS) To Announce First Quarter 2017 Financial Results And Host Conference Call On May 9, 2017 5/3/2017 7:31:20 AM